February 2009
Mayo Clinic Proceedings;Feb2009, Vol. 84 Issue 2, p208
Academic Journal
Correction notice
Corrections to the articles "Back to Wilson and Jungner: 10 Good Reasons to Screen for Type 2 Diabetes Mellitus" in the January 2009 issue and "Comparison of Cardiovascular Event Rates in Patients Without Cardiovascular Disease in Whom Atorvastatin or Simvastatin Was Newly Initiated" in the December 2008 issue are presented.


Related Articles

  • Resolution of Asymptomatic Myocardial Ischemia in Patients With Type 2 Diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) Study. Wackers, Frans J. Th.; Chyun, Deborah A.; Young, Lawrence H.; Heller, Gary V.; Iskandrian, Ami E.; Davey, Janice A.; Barrett, Eugene J.; Taillefer, Raymond; Wittlin, Steven D.; Filipchuk, Neil; Ratner, Robert E.; Inzucchi, Silvio E. // Diabetes Care;Nov2007, Vol. 30 Issue 11, p2892 

    OBJECTIVE -- The purpose of this study was to assess whether the prevalence of inducible myocardial ischemia increases over time in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS -- Participants enrolled in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study underwent...

  • Statins for Diabetics.  // Medical Update;2005, Vol. 31 Issue 2, p58 

    This article reports the findings of a study on diabetes, conducted by Neil R. Poulter and colleagues, as of October 2005. Published in the Diabetes Care, the study found that cholesterol-lowering atorvastatin (Lipitor) reduced cardiovascular problems in people with type 2 diabetes and high...

  • Increased risk of glucose intolerance and type 2 diabetes with statins: In people with a moderate or high risk of cardiovascular disease, benefits of statins still outweigh the risks. Byrne, Christopher D.; Wild, Sarah H. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/15/2011, Vol. 343 Issue 7827, p755 

    The article focuses on a clinical review which states that the drug statins causes type 2 diabetes and worsens glucose tolerance. It informs that the 4278 people out of 91 140 developed diabetes during four years of statins exposure. It also informs that an analysis of 2001 West of Scotland...

  • Endothelial Vasodilation Effects of Statins in Type 2 Diabetic Patients. Sowers, James R. // Diabetes Care;Jul2002, Vol. 25 Issue 7, p1242 

    Editorial. Presents a reply to a placebo-controlled, randomized study on the endothlial vasodilation effects of statins in type 2 diabetes. Effects of statins on cardiovascular disease; Reason behind the ineffectiveness of statin therapy in nitric oxide-mediated vasodilation in patients with...

  • EPIDEMIOLOGY--CARDIOVASCULAR DISEASE.  // Diabetes;2015 Supplement, Vol. 64, pA386 

    The article presents abstracts on medical topics, which include such studies as the risk factors for lack of statin therapy in patients with diabetes and coronary artery disease, the independent predictors of cardiovascular disease (CVD) events, and the incidence of cardiovascular disease and...

  • Atorvastatin did not prevent cardiovascular events or death in patients with type 2 diabetes receiving hemodialysis.  // ACP Journal Club;Jan/Feb2006, Vol. 144 Issue 1, p7 

    This article reports on a study conducted to examine the efficacy of atorvastatin in preventing cardiovascular events or death in patients with type 2 diabetes receiving hemodialysis. 1255 patients 18 to 80 years of age with type 2 diabetes who had been receiving maintenance hemodialysis for...

  • Atorvastatin reduced risk for major CV events in patients with CAD, CKD, diabetes. Blumenthal, Roger S. // Endocrine Today;10/10/2008, Vol. 6 Issue 18, p18 

    The article discusses research on the impact of lipid-lowering with high-dose atorvastatin on the risk for major cardiovascular events in patients with coronary artery disease, type 2 diabetes and chronic kidney disease (CKD). Results showed that patients with diabetes and CKD assigned to...

  • Cardiovascular and major journals. Evans, Marc // Diabetes Digest;2015, Vol. 14 Issue 2, p98 

    The article presents abstracts related to glucose-lowering therapy to reduce the cardiovascular disease (CV) risks in patients with type 2 diabetes (T2D) which include the use of biguanides and liraglutide in risk reduction, and the impact of glycaemic index (GI) on the risk factors in CV disease.

  • Efficacy of Low Dose of Rosuvastatin on Serum Lipid Profile in Japanese Type 2 Diabetic Patients. Urakaze, Masaharu; Kobashi, Chikaaki; Asamizu, Sachie; Din, Amal Khalifa Norel; Iwata, Minoru; Usui, Isao; Yamazaki, Katsuya; Kobayashi, Masashi // Diabetes;Jun2007 Supplement 1, Vol. 56, pA621 

    Atherosclerotic cardiovascular diseases are fatal complications in diabetic patients. For the prevention of those complications, the management of hyperglycaemia as well as dyslipidaemia and hypertension is really important. The most critical factor for cardiovascular events is LDL-C, and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics